PH12018502457B1 - Treatment for parkinson's disease - Google Patents
Treatment for parkinson's diseaseInfo
- Publication number
- PH12018502457B1 PH12018502457B1 PH12018502457A PH12018502457A PH12018502457B1 PH 12018502457 B1 PH12018502457 B1 PH 12018502457B1 PH 12018502457 A PH12018502457 A PH 12018502457A PH 12018502457 A PH12018502457 A PH 12018502457A PH 12018502457 B1 PH12018502457 B1 PH 12018502457B1
- Authority
- PH
- Philippines
- Prior art keywords
- alkyl
- haloalkyl
- hydrogen
- disease
- parkinson
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621019087 | 2016-06-02 | ||
| IN201621019185 | 2016-06-02 | ||
| PCT/IN2017/050224 WO2017208267A1 (en) | 2016-06-02 | 2017-06-02 | Treatment for parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12018502457A1 PH12018502457A1 (en) | 2019-10-21 |
| PH12018502457B1 true PH12018502457B1 (en) | 2022-01-12 |
Family
ID=59388123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018502457A PH12018502457B1 (en) | 2016-06-02 | 2018-11-22 | Treatment for parkinson's disease |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10849887B2 (enExample) |
| EP (2) | EP3463351B1 (enExample) |
| JP (1) | JP6974357B2 (enExample) |
| KR (1) | KR102508288B1 (enExample) |
| CN (1) | CN109475539B (enExample) |
| AU (1) | AU2017273415B2 (enExample) |
| CA (1) | CA3024976A1 (enExample) |
| CL (1) | CL2018003431A1 (enExample) |
| CY (1) | CY1125285T1 (enExample) |
| DK (1) | DK3463351T3 (enExample) |
| ES (1) | ES2914782T3 (enExample) |
| HR (1) | HRP20220683T1 (enExample) |
| HU (1) | HUE059387T2 (enExample) |
| IL (1) | IL263188B (enExample) |
| LT (1) | LT3463351T (enExample) |
| MX (1) | MX385276B (enExample) |
| MY (1) | MY193754A (enExample) |
| NZ (1) | NZ748592A (enExample) |
| PH (1) | PH12018502457B1 (enExample) |
| PL (1) | PL3463351T3 (enExample) |
| PT (1) | PT3463351T (enExample) |
| RS (1) | RS63243B1 (enExample) |
| SG (1) | SG11201810294QA (enExample) |
| SI (1) | SI3463351T1 (enExample) |
| SM (1) | SMT202200228T1 (enExample) |
| UA (1) | UA123018C2 (enExample) |
| WO (1) | WO2017208267A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2911040C (en) | 2012-05-02 | 2021-11-16 | Georgetown University | Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors |
| KR102508288B1 (ko) | 2016-06-02 | 2023-03-09 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 파킨슨병의 치료 |
| CN110606840A (zh) | 2018-06-15 | 2019-12-24 | 日产化学株式会社 | 5-炔基吡啶化合物的制造方法 |
| EP3883935A4 (en) | 2018-11-20 | 2022-08-10 | Georgetown University | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE AND LYSOSOMAL STORAGE DISORDERS |
| KR20220024463A (ko) * | 2019-06-11 | 2022-03-03 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 시뉴클레인병증에 대한 치료 |
| WO2021030783A1 (en) * | 2019-08-15 | 2021-02-18 | Duke University | Compositions and methods for the treatment cancer and cns disorders |
| AU2021317186A1 (en) | 2020-07-31 | 2023-03-16 | Sun Pharma Advanced Research Company Limited | N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of Alzheimer's Disease |
| US20250275953A1 (en) | 2022-05-02 | 2025-09-04 | Sun Pharma Advanced Research Company Ltd. | Vodobatinib for reducing progression of parkinson's disease |
| WO2025058473A1 (ko) | 2023-09-14 | 2025-03-20 | 주식회사 엑소스템텍 | 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012208388C1 (en) * | 2011-01-21 | 2017-04-27 | Sun Pharma Advanced Research Company Ltd | Diarylacetylene hydrazide containing tyrosine kinase inhibitors |
| CA2911040C (en) | 2012-05-02 | 2021-11-16 | Georgetown University | Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors |
| MX2017014752A (es) * | 2015-05-18 | 2018-03-23 | Sun Pharma Advanced Res Co Ltd | Nuevos etinos de amidoheteroaril aroil hidrazida. |
| KR102508288B1 (ko) * | 2016-06-02 | 2023-03-09 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 파킨슨병의 치료 |
-
2017
- 2017-06-02 KR KR1020187034626A patent/KR102508288B1/ko active Active
- 2017-06-02 DK DK17743097.2T patent/DK3463351T3/da active
- 2017-06-02 SM SM20220228T patent/SMT202200228T1/it unknown
- 2017-06-02 CN CN201780044265.3A patent/CN109475539B/zh active Active
- 2017-06-02 HU HUE17743097A patent/HUE059387T2/hu unknown
- 2017-06-02 CA CA3024976A patent/CA3024976A1/en active Pending
- 2017-06-02 JP JP2018563062A patent/JP6974357B2/ja active Active
- 2017-06-02 PL PL17743097T patent/PL3463351T3/pl unknown
- 2017-06-02 WO PCT/IN2017/050224 patent/WO2017208267A1/en not_active Ceased
- 2017-06-02 MX MX2018014944A patent/MX385276B/es unknown
- 2017-06-02 AU AU2017273415A patent/AU2017273415B2/en not_active Ceased
- 2017-06-02 PT PT177430972T patent/PT3463351T/pt unknown
- 2017-06-02 RS RS20220497A patent/RS63243B1/sr unknown
- 2017-06-02 US US16/304,914 patent/US10849887B2/en active Active
- 2017-06-02 NZ NZ748592A patent/NZ748592A/en unknown
- 2017-06-02 LT LTEPPCT/IN2017/050224T patent/LT3463351T/lt unknown
- 2017-06-02 ES ES17743097T patent/ES2914782T3/es active Active
- 2017-06-02 SG SG11201810294QA patent/SG11201810294QA/en unknown
- 2017-06-02 EP EP17743097.2A patent/EP3463351B1/en active Active
- 2017-06-02 EP EP22169420.1A patent/EP4085912A1/en active Pending
- 2017-06-02 HR HRP20220683TT patent/HRP20220683T1/hr unknown
- 2017-06-02 UA UAA201812407A patent/UA123018C2/uk unknown
- 2017-06-02 SI SI201731157T patent/SI3463351T1/sl unknown
- 2017-06-02 MY MYPI2018002187A patent/MY193754A/en unknown
-
2018
- 2018-11-21 IL IL263188A patent/IL263188B/en unknown
- 2018-11-22 PH PH12018502457A patent/PH12018502457B1/en unknown
- 2018-11-30 CL CL2018003431A patent/CL2018003431A1/es unknown
-
2020
- 2020-10-01 US US17/061,139 patent/US11583522B2/en active Active
-
2022
- 2022-05-18 US US17/747,472 patent/US11813252B2/en active Active
- 2022-05-27 CY CY20221100369T patent/CY1125285T1/el unknown
-
2023
- 2023-10-11 US US18/378,901 patent/US20240066014A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502457B1 (en) | Treatment for parkinson's disease | |
| PH12021550310A1 (en) | Novel sulfonamideurea compounds | |
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
| MY174284A (en) | Compounds for treating spinal muscular atrophy | |
| EA201700077A1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| EA201790713A1 (ru) | N-АЛКИЛАРИЛ-5-ОКСОАРИЛОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛЬНЫЕ НЕГАТИВНЫЕ АЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ NR2B | |
| EA201490269A1 (ru) | Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| CY1125082T1 (el) | Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα | |
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| EA201790626A1 (ru) | Макроциклические ингибиторы lrrk2-киназы | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
| PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
| MX2021006985A (es) | Metodos para el tratamiento de la depresión. | |
| MX2019006768A (es) | Peptidos antimicrobianos. | |
| EA201590074A1 (ru) | Производное бензодиоксола, способ его получения и его применение | |
| MX380758B (es) | Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo. | |
| PH12019501566B1 (en) | Amide compounds and use thereof | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| PH12020550549A1 (en) | Compositions for preventing or treating lupus |